Converting From Intramuscular to Oral Risperidone in a Nursing Home Resident

Prim Care Companion CNS Disord. 2023 Jul 27;25(4):22cr03430. doi: 10.4088/PCC.22cr03430.

Authors

Brian R MacNeill^{1

2}, Paula M Opatrny¹, Mark S Burke¹, Lecia J Heinen¹, Maurice W Dysken^{1

3}

Affiliations

¹ Minnesota Department of Veterans Affairs.
² Corresponding Author: Brian MacNeill, MA, BCBA, 20 W 12th St, Room 206, St Paul, Minnesota 55155 (brian.macneill@state.mn.us).
³ Minneapolis VA Health Care System, Minneapolis, Minnesota (Dysken).

PMID: 37506397
DOI: 10.4088/PCC.22cr03430

No abstract available

MeSH terms

Antipsychotic Agents* / adverse effects
Humans
Nursing Homes
Psychotic Disorders* / drug therapy
Risperidone / adverse effects

Substances

Risperidone
Antipsychotic Agents